Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The aim of the study is to assess the short-term benefit of the combination of basiliximab, EC-MPS and cyclosporine microemulsion with C2 monitoring on the prophylaxis of acute rejection in a population of de novo renal transplant patients at potential high risk of DGF.
A 3 Month, Multicenter, Open-label Study to Evaluate the Impact of the Immunosuppressive Combination of Enteric-Coated Mycophenolate Sodium (EC- MPS), Basiliximab and Cyclosporine for Microemulsion With C2 Monitoring, on Efficacy and Safety Outcomes in de Novo Kidney Transplant Recipients at Potential High Risk of DGF.
Study Start Date
Actual Primary Completion Date
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 70 Years (Adult, Senior)
Sexes Eligible for Study:
- Age 18-70 years old
Patients receiving a primary or secondary cadaveric or living donor kidney
Patients who have given written informed consent for study participation
Females capable of becoming pregnant must have a negative pregnancy test at baseline and are required to practice birth control for the duration of the study and at least for four months following the last dose of basiliximab.
Recipient of multi-organ transplants or previously transplanted organs other than kidney
Recipient of dual kidney transplants
Recipient of a transplanted kidney from a Non-Heart Beating Donor (NHBD)
Recipient of a HLA identical living-donor kidney
Patients with a PRA level (past or current level) greater than 20%
Patients anticipated by investigators to require induction therapy with OKT3, ATGAM, or Thymoglobulin for any reason
Patients with any medical condition which, in the opinion of the investigator, would preclude the patient from participating in the study
Cold ischemia time larger than 36 hours.
Patients who have received an investigational drug or therapy within one month prior to study entry or if such therapy is to be instituted post-transplantation.
Female transplant candidates who are pregnant, lactating, or of childbearing potential and not willing to practice an acceptable method of contraception
Patients with a known hypersensitivity to cyclosporine
Patients with a known malignancy or a history of malignancy, other than successfully treated non-metastatic basal or squamous cell carcinoma of the skin
Known HIV positive antibody status
Evidence of any clinically relevant (per investigator determination) active infection
Patients unable to participate in the study for the full 3-month study period
Other protocol-defined exclusion criteria may apply.